ATE164067T1 - Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen - Google Patents

Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen

Info

Publication number
ATE164067T1
ATE164067T1 AT94902019T AT94902019T ATE164067T1 AT E164067 T1 ATE164067 T1 AT E164067T1 AT 94902019 T AT94902019 T AT 94902019T AT 94902019 T AT94902019 T AT 94902019T AT E164067 T1 ATE164067 T1 AT E164067T1
Authority
AT
Austria
Prior art keywords
riluzole
pct
neurological injury
treat traumatic
date
Prior art date
Application number
AT94902019T
Other languages
English (en)
Inventor
Adam Doble
Erik Louvel
Jeremy Pratt
Jean-Marie Stutzmann
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Application granted granted Critical
Publication of ATE164067T1 publication Critical patent/ATE164067T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT94902019T 1992-12-16 1993-12-10 Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen ATE164067T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9215148A FR2699077B1 (fr) 1992-12-16 1992-12-16 Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.

Publications (1)

Publication Number Publication Date
ATE164067T1 true ATE164067T1 (de) 1998-04-15

Family

ID=9436652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94902019T ATE164067T1 (de) 1992-12-16 1993-12-10 Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen

Country Status (23)

Country Link
US (1) US5830907A (de)
EP (3) EP0674520A1 (de)
JP (3) JPH08504429A (de)
KR (3) KR100298808B1 (de)
AT (1) ATE164067T1 (de)
AU (3) AU678795B2 (de)
CA (3) CA2151603A1 (de)
CZ (3) CZ284420B6 (de)
DE (1) DE69317578T2 (de)
DK (1) DK0674512T3 (de)
ES (1) ES2113635T3 (de)
FR (1) FR2699077B1 (de)
GR (1) GR3026403T3 (de)
HU (3) HUT71839A (de)
IL (3) IL108053A0 (de)
MX (3) MX9307882A (de)
NO (3) NO952229L (de)
PL (3) PL309346A1 (de)
RU (1) RU2142800C1 (de)
SK (3) SK78595A3 (de)
UA (1) UA41906C2 (de)
WO (3) WO1994013296A1 (de)
ZA (3) ZA939401B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
FR2733684B1 (fr) 1995-05-03 1997-05-30 Cird Galderma Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
ES2203985T3 (es) 1997-09-05 2004-04-16 Glaxo Group Limited Derivados de 2,3-diaril-pirazolo(1,5)piridazina, su preparacion y su uso como inhibidores de la ciclooxigenasa 2(cox-2)`.
GB9808015D0 (en) * 1998-04-15 1998-06-17 United Medical And Dental Scho Protection of the nervous system from the effects of inflammatory disease
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
EP1173175A1 (de) * 1999-04-29 2002-01-23 Centre National De La Recherche Scientifique (Cnrs) Verfahren zur vorbeugung von ischämischen ruckenmarkverletzungen hervorgerufen durch aorta abklemmen
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
RU2240113C1 (ru) * 2003-01-23 2004-11-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова Способ экстренной медикаментозной помощи при острой травме спинного мозга
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
CA2661448A1 (en) 2005-08-25 2007-03-01 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
SG11201407300VA (en) * 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en) 2012-09-08 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (de) 2014-09-29 2020-03-18 Cellix Bio Private Limited Verbindungen und zusammensetzungen zur behandlung multipler sklerose
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
WO2016088132A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 炎症及び疼痛の治療のための組成物及び方法
KR102279993B1 (ko) 2015-09-23 2021-07-21 엑스더블유파마 리미티드 감마-하이드록시부티르산의 전구체 및 이의 조성물 및 용도
BR112019020464A2 (pt) 2017-03-30 2020-04-28 Xw Laboratories Inc. compostos derivados de heteroarila bicíclica, composição farmacêutica compreendendo os ditos compostos, adesivo transdérmico compreendendo a dita composição e uso terapêutico dos compostos e composição
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US20200289476A1 (en) * 2017-11-28 2020-09-17 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
EP3856719B1 (de) 2018-09-30 2023-06-07 XWPharma Ltd. Verbindungen als neuronale histaminrezeptor-3-antagonisten und deren verwendungen
TW202547822A (zh) 2019-12-20 2025-12-16 香港商凱瑞康寧有限公司 ４－纈胺醯氧基丁酸的合成方法
EP4167966A1 (de) 2020-06-18 2023-04-26 XWPharma Ltd. Pharmazeutische granulate wasserlöslicher pharmazeutischer wirkstoffe
EP4167971A1 (de) 2020-06-18 2023-04-26 XWPharma Ltd. Granulate mit kontrollierter freisetzung von wasserlöslichen pharmazeutischen wirkstoffen
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
CN119970650A (zh) 2020-10-05 2025-05-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的修饰释放组合物
EP4308086B1 (de) 2021-03-19 2025-10-15 XWPharma Ltd. Pharmakokinetik von formulierungen mit kombinierter freisetzung eines gamma-hydroxybuttersäurederivats
WO2025216887A1 (en) 2024-04-11 2025-10-16 Dow Global Technologies Llc High internal phase emulsion
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021121B1 (de) * 1979-06-01 1983-05-11 The Wellcome Foundation Limited 1,2,4-Triazin-Derivate, Verfahren zur Herstellung dieser Verbindungen und sie enthaltende pharmazeutische Zusammensetzungen
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
US5240948A (en) * 1989-12-13 1993-08-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. 3-(3-alkylthiopropyl)benzothiazoline derivatives, their preparation and the medicament containing them
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE69233479T2 (de) * 1991-02-08 2006-03-16 Scion Pharmaceuticals, Inc., Medford Substituierte Guanidine und Derivate hiervon als Modulatoren der Freisetzung von Neurotransmittern und neue Methode zur Identifizierung von Inhibitoren der Neurotransmitter-Freisetzung
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
HUT71839A (en) 1996-02-28
JPH08504429A (ja) 1996-05-14
SK78695A3 (en) 1996-05-08
KR100298808B1 (ko) 2001-11-22
JPH08504430A (ja) 1996-05-14
AU5654094A (en) 1994-07-04
HUT71814A (en) 1996-02-28
CZ284420B6 (cs) 1998-11-11
RU2142800C1 (ru) 1999-12-20
SK279759B6 (sk) 1999-03-12
AU5702094A (en) 1994-07-04
IL108052A0 (en) 1994-04-12
KR950703965A (ko) 1995-11-17
NO952229D0 (no) 1995-06-06
CA2151604C (fr) 2005-09-20
NO952230L (no) 1995-06-06
AU5653994A (en) 1994-07-04
IL108051A (en) 1999-05-09
ZA939400B (en) 1994-08-19
FR2699077A1 (fr) 1994-06-17
HUT71812A (en) 1996-02-28
JP3712239B2 (ja) 2005-11-02
NO952228L (no) 1995-06-06
WO1994013288A1 (fr) 1994-06-23
HU9501751D0 (en) 1995-08-28
IL108053A0 (en) 1994-04-12
WO1994013296A1 (fr) 1994-06-23
PL309347A1 (en) 1995-10-02
ES2113635T3 (es) 1998-05-01
MX9307883A (es) 1994-06-30
CA2151601A1 (fr) 1994-06-23
US5830907A (en) 1998-11-03
PL309346A1 (en) 1995-10-02
KR950703968A (ko) 1995-11-17
HU217133B (hu) 1999-11-29
NO307027B1 (no) 2000-01-31
EP0674512B1 (de) 1998-03-18
EP0674520A1 (de) 1995-10-04
PL309348A1 (en) 1995-10-02
NO952228D0 (no) 1995-06-06
KR950703954A (ko) 1995-11-17
NO952230D0 (no) 1995-06-06
SK78795A3 (en) 1996-05-08
ZA939399B (en) 1994-08-22
AU678795B2 (en) 1997-06-12
NO952229L (no) 1995-06-06
CZ154795A3 (en) 1995-11-15
SK78595A3 (en) 1996-05-08
GR3026403T3 (en) 1998-06-30
CA2151604A1 (fr) 1994-06-23
CZ154695A3 (en) 1995-11-15
EP0674518A1 (de) 1995-10-04
IL108051A0 (en) 1994-04-12
DK0674512T3 (da) 1998-05-25
MX9307882A (es) 1994-06-30
UA41906C2 (uk) 2001-10-15
CZ154595A3 (en) 1995-11-15
DE69317578D1 (de) 1998-04-23
HU9501752D0 (en) 1995-08-28
HU9501753D0 (en) 1995-08-28
ZA939401B (en) 1994-08-19
EP0674512A1 (de) 1995-10-04
DE69317578T2 (de) 1998-07-23
FR2699077B1 (fr) 1995-01-13
CA2151603A1 (fr) 1994-06-23
WO1994013298A1 (fr) 1994-06-23
MX9307884A (es) 1994-06-30
JPH08504428A (ja) 1996-05-14

Similar Documents

Publication Publication Date Title
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE196847T1 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69310528D1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
ATE241981T1 (de) Verwendung von 4-aminopyridin zur behandlung von schmerz und spastik folgende einer verletzung des rückenmarks
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
ATE190839T1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification